Evaluation of the bioequivalence of two products containing esomeprazole under fasting conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexium 40 mg (Comparator). An open, randomized, single dose, four-period, replicate, crossover trial in healthy volunteers

2024-512401-89-00 Protocol CBP23002 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 12 Jun 2025 · End 8 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CBP23002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 54
Countries 1
Sites 1

No therapeutic indication in the current trial with healthy volunteers.

Key facts

Sponsor
CCDRD Cooperative Clinical Drug Research and Development AG, BePharBel Manufacturing
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
12 Jun 2025 → 8 Oct 2025
Decision date (initial)
2025-03-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No therapeutic indication in the current trial with healthy volunteers.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CCDRD Cooperative Clinical Drug Research and Development AG

Sponsor organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Address
Dahlwitz, Lindenallee 70, Dahlwitz-Hoppegarten Lindenallee 70 Dahlwitz-Hoppegarten
City
Hoppegarten
Postcode
15366
Country
Germany

Scientific contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project manager

Public contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project manager

BePharBel Manufacturing

Sponsor organisation
BePharBel Manufacturing
Address
Rue Du Luxembourg 13
City
Courcelles
Postcode
6180
Country
Belgium

Scientific contact point

Organisation
BePharBel Manufacturing
Contact name
Olivier Laloux

Public contact point

Organisation
BePharBel Manufacturing
Contact name
Vincent Stéphenne

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 54 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Ended
Bed space for short term stay at Diagnostic & Consultative Centre 'Ascendent' Ltd.
Bed space for short term stay, 47 'Bacho Kiro' str., 1202, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-06-12 2025-10-08 2025-06-12 2025-09-03

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-20 Bulgaria Acceptable
2025-03-04
2025-03-10